Department of Physiology, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Europace. 2010 Mar;12(3):356-63. doi: 10.1093/europace/eup429. Epub 2010 Jan 7.
To examine the effect of n-3 polyunsaturated fatty acid (PUFA) treatment on the incidence of post-operative atrial fibrillation (POAF).
A prospective, randomized, double-blinded, placebo-controlled trial was conducted in patients admitted for coronary artery bypass grafting and/or valvular repair surgery. The patients received either n-3 PUFA capsules, containing a daily dose of 1240 mg eicosapentaenoic acid and 1000 mg docosahexaenoic acid, or olive oil capsules for 5-7 days prior to surgery and post-operatively until hospital discharge. The endpoint was POAF, defined as an episode detected by continuous electrocardiographic monitoring, lasting >5 min. A total of 170 patients were enrolled in the study, and 168 patients underwent surgery. Their median age was 67 (range 43-82) years, and 79.2% were males. There was no difference in baseline characteristics between the n-3 PUFA group (n = 83) and the placebo group (n = 85), and the incidence of POAF was 54.2 and 54.1% (P = 0.99), respectively. Factors associated with POAF included advanced age, peak post-operative C-reactive protein level, valvular surgery, lower body mass index, and non-smoking, but n-3 PUFA concentration in plasma lipids was not associated with POAF.
There is no evidence for a beneficial effect of treatment with n-3 PUFA on the occurrence of POAF in patients undergoing open heart surgery.
研究 n-3 多不饱和脂肪酸（PUFA）治疗对术后心房颤动（POAF）发生率的影响。
本研究为前瞻性、随机、双盲、安慰剂对照试验，纳入了因冠状动脉旁路移植术和/或瓣膜修复手术而住院的患者。患者在术前 5-7 天和术后直至出院期间，每天服用 n-3 PUFA 胶囊（含 1240mg 二十碳五烯酸和 1000mg 二十二碳六烯酸）或橄榄油胶囊。研究终点为 POAF，定义为通过连续心电图监测发现的持续 >5 分钟的发作。共有 170 例患者入组，其中 168 例接受了手术。他们的中位年龄为 67 岁（范围 43-82 岁），79.2%为男性。n-3 PUFA 组（n=83）和安慰剂组（n=85）之间的基线特征无差异，POAF 的发生率分别为 54.2%和 54.1%（P=0.99）。与 POAF 相关的因素包括年龄较大、术后 C 反应蛋白峰值、瓣膜手术、较低的体重指数和不吸烟，但血浆脂质中的 n-3 PUFA 浓度与 POAF 无关。
对于接受心脏直视手术的患者，n-3 PUFA 治疗对 POAF 的发生没有有益作用。
